14-3-3η: Informing the RA Continuum of Care

14-3-3η Informs the RA Continuum of Care

Vancouver, BC – October 28, 2016. At the world’s premier rheumatology conference, the American College of Rheumatology Annual Meeting (ACR) in Washington, DC, November 11-16, international investigators from Sweden, the United States, Romania and Japan will present data on 14-3-3η blood testing in Rheumatoid Arthritis (RA).

“These studies build on and independently validate previously published clinical data that 14-3-3η uniquely complements a clinical assessment and other blood test to optimize RA patient management along the continuum of disease,” says Dr. Yoshiya Tanaka, Professor & Chairman, of The First Department of Internal Medicine, School of Medicine University of Occupational & Environmental Health, Japan.

A clinical assessment and serological markers such as CRP, give an accurate view of the patient’s clinical disease activity. As a complement to that, 14-3-3η reflects active cellular joint damage processes that are underway, which can’t be seen on clinical exam or informed by acute phase reactants. “In agreement with 14-3-3η’s role in the joint damage pathway and based on consistent observations across cohorts of patients, from very early RA right through to established disease, persistently elevated 14-3-3η blood levels predict rapid joint damage progression, even in patients who achieve clinical remission,” says Dr. Gilles Boire, Professor in the Division of Rheumatology of the Faculty of Medicine at the Université de Sherbrooke. He adds, “Elevated 14-3-3η levels potentially mandate earlier and tighter therapeutic strategies to treat to radiographic remission.”

14-3-3η ACR 2016 Conference Proceedings

Title & Author Date & Location
Evaluation of 14-3-3η as a Tool for Diagnosis of Early RA in a European Cohort
Author: Monika Hansson
Nov 13, 4:30 – 6:00pm
Ballroom A
Oral Presentation Number: 1037
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Author: Dmitry Karayev
Nov 13, 9:00 – 11:00am
Poster Hall: Hall A
Poster Number: 494
Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?
Author: Bogdan Ion Gavrila
Nov 15, 9:00 – 11:00am
Poster Hall: Hall C
Poster Number: 2648
Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Author: Shintaro Hirata
Nov 15, 9:00-11:00am
Poster Hall: Hall C
Poster Number: 2521

Expanding Access to 14-3-3η Blood Testing in the United States

During ACR, information regarding 14-3-3η testing in the US can be found at the following exhibit locations:

Quest Diagnostics: 722
LabCorp (Laboratory Corporation of America): 2112
RDL Reference Laboratory: 1531

Earlier RA Diagnosis and Appropriate Treatment Improves Outcomes

The 14-3-3η test is available in Canada, Japan, Europe and Australia under the registered trade name JOINTstat™.

lifelabs